Vontobel Holding Ltd. Sells 14,970 Shares of DexCom, Inc. $DXCM

Vontobel Holding Ltd. reduced its position in DexCom, Inc. (NASDAQ:DXCM) by 53.2% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 13,171 shares of the medical device company’s stock after selling 14,970 shares during the quarter. Vontobel Holding Ltd.’s holdings in DexCom were worth $1,137,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the company. TD Waterhouse Canada Inc. boosted its holdings in shares of DexCom by 17.4% in the third quarter. TD Waterhouse Canada Inc. now owns 7,873 shares of the medical device company’s stock valued at $680,000 after acquiring an additional 1,169 shares in the last quarter. V Square Quantitative Management LLC increased its stake in shares of DexCom by 8.6% during the third quarter. V Square Quantitative Management LLC now owns 4,301 shares of the medical device company’s stock worth $371,000 after acquiring an additional 339 shares during the period. Curated Wealth Partners LLC purchased a new position in DexCom during the third quarter worth about $333,000. Mather Group LLC. raised its holdings in DexCom by 27.7% during the third quarter. Mather Group LLC. now owns 563 shares of the medical device company’s stock worth $49,000 after purchasing an additional 122 shares in the last quarter. Finally, Fortitude Family Office LLC raised its holdings in DexCom by 293.8% during the third quarter. Fortitude Family Office LLC now owns 760 shares of the medical device company’s stock worth $66,000 after purchasing an additional 567 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on DXCM shares. Wells Fargo & Company raised their price objective on shares of DexCom from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, July 31st. Piper Sandler reiterated an “overweight” rating and set a $95.00 target price (up from $88.00) on shares of DexCom in a research report on Friday, July 31st. Argus boosted their target price on DexCom from $86.00 to $96.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Truist Financial set a $102.00 target price on DexCom and gave the stock a “buy” rating in a research note on Friday, September 18th. Finally, Raymond James Financial reissued a “strong-buy” rating and issued a $94.00 price target on shares of DexCom in a report on Friday, July 31st. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $92.43.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $85.98 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. DexCom, Inc. has a one year low of $54.11 and a one year high of $92.59. The firm has a market capitalization of $32.45 billion, a P/E ratio of 33.98, a PEG ratio of 1.44 and a beta of 1.48. The company’s fifty day moving average is $87.58 and its two-hundred day moving average is $76.12.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same quarter last year, the firm posted $0.48 EPS. The business’s revenue was up 13.1% compared to the same quarter last year. Analysts forecast that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Insider Activity

In other DexCom news, EVP Michael Brown sold 1,700 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $85.48, for a total value of $145,316.00. Following the completion of the transaction, the executive vice president directly owned 98,185 shares of the company’s stock, valued at approximately $8,392,853.80. This trade represents a 1.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 2,000 shares of DexCom stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $85.32, for a total transaction of $170,640.00. Following the sale, the director owned 48,852 shares of the company’s stock, valued at approximately $4,168,052.64. The trade was a 3.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 24,257 shares of company stock valued at $2,049,173 in the last quarter. Insiders own 0.28% of the company’s stock.

DexCom Profile

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.